Pfizer Inc. (NYSE:PFE) Stock Holdings Boosted by Richard C. Young & CO. LTD.

Richard C. Young & CO. LTD. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 1.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 196,181 shares of the biopharmaceutical company’s stock after purchasing an additional 2,417 shares during the quarter. Pfizer comprises 1.6% of Richard C. Young & CO. LTD.’s portfolio, making the stock its 26th largest holding. Richard C. Young & CO. LTD.’s holdings in Pfizer were worth $8,499,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Evolution Wealth Advisors LLC purchased a new stake in shares of Pfizer in the second quarter valued at $34,000. IMA Wealth Inc. lifted its holdings in shares of Pfizer by 144.5% in the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 477 shares in the last quarter. Winch Advisory Services LLC lifted its holdings in shares of Pfizer by 69.6% in the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 336 shares in the last quarter. Ruggie Capital Group purchased a new stake in shares of Pfizer in the fourth quarter valued at $44,000. Finally, Financial Gravity Wealth Inc. lifted its holdings in shares of Pfizer by 33.2% in the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 257 shares in the last quarter. 71.58% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE:PFE traded down $0.74 during midday trading on Friday, hitting $34.34. 20,323,181 shares of the stock were exchanged, compared to its average volume of 35,329,740. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $46.47. The business’s fifty day simple moving average is $39.60 and its two-hundred day simple moving average is $41.43. The company has a market capitalization of $192.87 billion, a PE ratio of 11.45, a P/E/G ratio of 2.78 and a beta of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company earned $0.77 earnings per share. Pfizer’s quarterly revenue was down 1.5% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.8 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be issued a dividend of $0.36 per share. The ex-dividend date is Thursday, August 1st. This represents a $1.44 annualized dividend and a dividend yield of 4.19%. Pfizer’s dividend payout ratio is 48.00%.

A number of research firms have recently issued reports on PFE. UBS Group restated a “neutral” rating and issued a $43.00 target price on shares of Pfizer in a report on Monday, August 5th. Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. Barclays restated a “hold” rating and issued a $41.00 target price on shares of Pfizer in a report on Thursday, May 9th. JPMorgan Chase & Co. set a $46.00 target price on Pfizer and gave the company a “neutral” rating in a report on Monday, July 29th. Finally, Morgan Stanley lowered Pfizer from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $48.00 to $40.00 in a report on Tuesday, July 30th. Fourteen research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $46.67.

In other Pfizer news, insider Alexander R. Mackenzie sold 30,000 shares of the stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the transaction, the insider now directly owns 80,094 shares of the company’s stock, valued at $3,524,136. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Frank A. Damelio sold 153,184 shares of the stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the transaction, the executive vice president now directly owns 489,647 shares in the company, valued at $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Fundamental Analysis

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.